The good news is that SVM is up a solid 17.64% since my recommendation on Nov. 22 — and is actually up 45.5% since it bottomed on Jan. 24.
The less good news is that the options I recommended — the March $12.50 calls — are now just about back up to even — actually down 3.13% based on yesterday’s close. That was because SVM corrected substantially in January, and has been digging itself out of a deep hole.
With the options expiring in a little more than two weeks, I am recommending that you sell your options today. You roughly will break even on this trade, but with so little time remaining on the options, I don’t want you to risk any more on this position.
I am also recommending that with silver so overbought, and uncertainty in global markets high, you sell your SVM stock as well to lock in your 17.64% gains. We will be returning to the silver theme in future recommendations.
In addition, I am recommending that you sell half of your June 2011 $120 call options in Novo Nordisk (NVO) to lock in a 43.94% gain. With global stock markets increasingly unsteady, that’s not a bad return for a position you got into on Feb. 14!
With your remaining options expiring in June, and the fundamentals of Novo Nordisk still in place, hold on to both the stock and your remaining options for potentially bigger gains, still.